A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH

A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid (OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, NASH treatment) trial. However, genetic pre...

Full description

Bibliographic Details

Published in:	Hepatology Communications
Main Authors:	Samer Gawrieh, Xiuqing Guo, Jingyi Tan, Marie Lauzon, Kent D. Taylor, Rohit Loomba, Oscar W. Cummings, Sreekumar Pillai, Pallav Bhatnagar, Kris V. Kowdley, Katherine Yates, Laura A. Wilson, Yii‐Der Ida Chen, Jerome I. Rotter, Naga Chalasani, NASH Clinical Research Network
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2019-12-01
Online Access:	https://doi.org/10.1002/hep4.1439